Floatz logo

VONOPRAZAN

High-dose Dual Therapy

Nanjing First Hospital, Nanjing Medical UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the High-dose Dual Therapy cohort.

Asset / SponsorPhaseRating
Amoxicillin
Nanjing First Hospital, Nanjing Medical University
N/AD

Same molecule, other indications

VONOPRAZAN is also rated in:

HELICOBACTER PYLORI INFECTIONSDormant
BB
Indicative ·
65 / 100
View asset →
esophageal varicesDormant
B
Indicative ·
60 / 100
View asset →
Metabolic SyndromeDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →